Brighton Jones’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$113K Buy
27,337
+604
+2% +$2.05K ﹤0.01% 1313
2026
Q2
$98.1K Buy
26,733
+602
+2% +$2K ﹤0.01% 1311
2026
Q1
$80.2K Buy
+26,131
New +$101K ﹤0.01% 1141
2025
Q4
– Sell
-27,727
Closed -$135K – 766
2025
Q3
$135K Sell
27,727
-1,582
-5% -$8.31K ﹤0.01% 983
2025
Q2
$148K Buy
29,309
+8,156
+39% +$40.1K ﹤0.01% 879
2025
Q1
$112K Buy
21,153
+892
+4% +$6.5K ﹤0.01% 676
2024
Q4
$137K Buy
20,261
+6,699
+49% +$45K ﹤0.01% 659
2024
Q3
$89.4K Buy
+13,562
New +$97.2K ﹤0.01% 562

Other funds holding RXRX

Brighton Jones's RXRX Position: Q3 2026 in Review

Brighton Jones increased its Recursion Pharmaceuticals (RXRX) stake by 2.3% in Q3 2026, buying an estimated $2.05K and bringing the position to 27,337 shares worth $113K. The position accounts for ﹤0.01% of the portfolio, ranked #1313.

Brighton Jones first reported a position in RXRX in Q3 2024 and has held it in 8 quarters since. The position peaked at $148K in Q2 2025. 291 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Brighton Jones held 27,337 shares of Recursion Pharmaceuticals worth $113K as of Q3 2026.
  • Brighton Jones bought 604 Recursion Pharmaceuticals shares in Q3 2026, an estimated $2.05K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Brighton Jones's portfolio in Q3 2026, its #1313 holding.
  • Brighton Jones first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Brighton Jones's Recursion Pharmaceuticals position peaked at $148K in Q2 2025.
  • 291 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.